Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Cencora (COR) Stock Forecast & Price Target

Cencora logo
$330.77 -7.71 (-2.28%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$330.56 -0.20 (-0.06%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
4
Buy
14

Based on 18 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for COR.

Consensus Price Target

$366.44
10.78% Upside
According to the 18 analysts' twelve-month price targets for Cencora, the average price target is $366.44. The highest price target for COR is $400.00, while the lowest price target for COR is $310.00. The average price target represents a forecasted upside of 10.78% from the current price of $330.77.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COR Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
14 Buy rating(s)
13 Buy rating(s)
9 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$366.44$369.19$364.93$324.91
Forecasted Upside10.78% Upside20.21% Upside17.18% Upside-2.43% Downside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cencora Stock vs. The Competition

TypeCencoraHealthcare CompaniesBroader Market
Consensus Rating Score
2.78
2.32
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside10.78% Upside1,400.11% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent COR News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/22/2026
Robert W. Baird logo
Robert W. Baird
3 of 5 stars
David Rodgers
3 of 5 stars
Boost TargetOutperform$373.00 ➝ $375.00+10.15%
10/20/2026
Argus logo
Argus
3 of 5 stars
David Toung
4 of 5 stars
Boost TargetBuy$340.00 ➝ $380.00+11.74%
10/16/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Kevin Caliendo
Kevin Caliendo
3 of 5 stars
Lower TargetBuy$430.00 ➝ $400.00+16.81%
10/7/2026Boost TargetOutperform$380.00 ➝ $388.00+21.42%
10/6/2026 UpgradeBuy (B-) ➝ Buy (B)
9/8/2026Reiterated RatingSector Perform$330.00+0.91%
8/11/2026Boost TargetOverweight$331.00 ➝ $395.00+21.85%
8/7/2026Boost TargetOverweight$342.00 ➝ $346.00+7.00%
8/7/2026Boost TargetOverweight$382.00 ➝ $390.00+20.86%
8/6/2026 Reiterated RatingOutperform$330.00 ➝ $350.00+10.18%
8/6/2026Reiterated RatingBuy
7/21/2026Boost Target$285.00 ➝ $310.00-4.73%
6/10/2026Lower TargetOverweight$425.00 ➝ $350.00+25.38%
4/28/2026Initiated CoverageMarket Perform
1/22/2026UpgradeUnderperform ➝ Buy
11/25/2025 Boost TargetBuy$371.00 ➝ $389.00+19.52%
11/10/2025Boost TargetBuy$350.00 ➝ $400.00+10.23%
11/6/2025Boost TargetOutperform$340.00 ➝ $380.00+7.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:33 PM ET.


Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Cencora, Inc.:

  • Cencora, Inc. recently announced a definitive agreement to acquire the remaining 96% stake in American Oncology Network for approximately $2.4 billion, a strategic move that adds about 350 physicians to its network and strengthens its support for community oncology practices, potentially expanding its provider network and oncology-related revenue opportunities.
  • Analyst sentiment remains positive with recent price target increases, such as Robert W. Baird raising its target to $375.00 and Argus lifting its target to $380.00, both maintaining buy or outperform ratings, which signals confidence in the company's growth prospects and suggests potential upside from the current stock price of $330.77.
  • The company demonstrated strong financial performance in its most recent quarterly earnings report, beating analysts' consensus estimates with earnings per share of $4.48 compared to the expected $4.35, while also reporting revenue of $84.75 billion, which exceeded the consensus estimate of $84.31 billion and represented a 5.1% year-over-year increase.
  • Short interest in Cencora, Inc. has been declining over recent months, with the number of shares shorted dropping to 3,919,355 as of September 30, 2026, down from 5,872,438 in July 2026, indicating that fewer investors are betting against the stock and suggesting a shift in market sentiment toward the company.
  • Institutional investors continue to show interest in the stock, with 26 exchange-traded funds adding to their Cencora holdings in mid-October 2026, and several hedge funds, such as Nisa Investment Advisors LLC, increasing their positions in the third quarter, which reflects ongoing institutional demand and confidence in the company's long-term value.

Cencora
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Cencora, Inc. for these reasons:

  • The $2.4 billion acquisition of American Oncology Network, while strategically attractive, introduces risks related to the purchase price, financing, and integration costs, and investors will need to assess the company's ability to generate sufficient returns from the expanded physician platform to justify the investment.
  • Some analysts have taken a more cautious stance, with UBS lowering its price target to $400, which, although still above the current trading level, creates a counterpoint to the more bullish revisions from other firms and suggests potential limitations in the stock's near-term upside.
  • Insider selling activity has been notable, with EVP Elizabeth Campbell selling 11,300 shares in August 2026 and CEO Robert P. Mauch selling 5,096 shares in January 2026, which may signal that company executives are taking advantage of higher stock prices to reduce their personal holdings.
  • The company's debt-to-equity ratio stands at 3.53, indicating a relatively high level of leverage, which could limit its financial flexibility and increase its vulnerability to economic downturns or rising interest rates, potentially affecting its ability to fund future acquisitions or operations.
  • Cencora, Inc. experienced a significant drop in its stock price following its May 2026 earnings report, hitting a 52-week low of $244.82, which suggests that the market may be skeptical about the company's ability to sustain its growth trajectory or manage its costs effectively in the face of competitive pressures.

COR Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $366.44, with a high forecast of $400.00 and a low forecast of $310.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COR shares.

According to analysts, Cencora's stock has a predicted upside of 10.78% based on their 12-month stock forecasts.

Over the previous 90 days, Cencora's stock had 2 upgrades by analysts.

Analysts like Cencora more than other "healthcare" companies. The consensus rating for Cencora is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how COR compares to other companies.


MarketBeat monitors more than a dozen sources for Cencora analyst ratings, with the most recent rating issued on 10/22/2026.
From Our Partners